Allosteric inhibition of Taspase1′s pathobiological activity by enforced dimerization in vivo

Taspase1 mediates cleavage of the mixed lineage leukemia (MLL) protein and leukemia‐provoking MLL fusions and promotes solid malignancies. Currently, no effective and specific Taspase1 inhibitors are available, precluding its therapeutic exploitation. As the Taspase1 proenzyme is autoproteolytically cleaved and assumed to assemble into an active αββα heterodimer, we attempted to interfere with its activity by targeting Taspase1′s dimerization. Notably, enforced expression of inactive Taspase1 mutants, aiming to inhibit formation of active protease dimers, was not inhibitory. Immunoprecipitation, gel filtration, and in vivo protein interaction assays revealed that active Taspase1 exists predominantly as an αβ monomer in living cells, providing an explanation why overexpression of inactive mutants was not trans ‐dominant. To alternatively test the biological consequences of enforced dimerization, we engineered Taspase1 variants containing the Jun/Fos dimerization motif. In absence of the respective interaction partners, the protease fusions were fully active, while enforcing dimerization by coexpression significantly inhibited processing of several target proteins in living cells. Our study provides the first evidence that Taspase1 is already active as an αβ monomer, arguing against heterocomplex formation being required for its pathobiological activity. Thus, it clearly supports strategies aiming to inhibit the cancer‐promoting activity of Taspase1 by the identification of chemical decoys enforcing its dimerization.—Bier, C., Knauer, S. K., Wünsch, D., Kunst, L., Scheiding, S., Kaiser, M., Ottmann, C., Krämer, O. H., Stauber, R. H. Allosteric inhibition of Taspase1′s pathobiological activity by enforced dimerization in vivo . FASEB J. 26, 3421–3429 (2012). www.fasebj.org